Log In
BCIQ
Print this Print this
 

Baremsis, IV amisulpride (formerly ACA1421, APD421)

  Manage Alerts
Collapse Summary General Information
Company Acacia Pharma Group plc
DescriptionLow-dose IV formulation of amisulpride, an off-patent dopamine D2 and D3 receptor (DRD3) antagonist
Molecular Target Dopamine D2 receptor ; Dopamine D3 receptor (DRD3)
Mechanism of ActionDopamine D2 receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationEmesis
Indication DetailsPrevent cisplatin-induced vomiting; Prevent postoperative nausea and vomiting (PONV); Treat and prevent chemotherapy-induced nausea & vomiting (CINV) in cancer patients receiving cisplatin; Treat postoperative nausea and vomiting (PONV)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today